Phesi has conducted a mid-year analysis of clinical trials conducted globally in the first six months of 2024. The analysis of 66,935 clinical trials reveals the top five most studied diseases are  breast cancer, solid tumor, stroke, prostate cancer and type 2 diabetes.

Key findings: 

• Covid-19 is no longer in the top five most studied disease indications, replaced by type 2 diabetes 
• Phase II study attrition continues to rise  with 32% of trials being terminated in Phase II so far in 2024 
• Protocol design with higher degrees of precision is required to drive down costs and get therapies to market faster